EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Redefining functional high‐risk multiple myeloma in the context of upfront quadruplet therapy and autologous stem cell transplantation

Gayathri Ravi, Binod Dhakal iD, Natalie S Callander, Eva Medvedova, Bhagirathbhai R Dholaria iD, Kelly N Godby, Susan Bal, Forest Huls, Rebecca W Silbermann, Luciano J Costa iD

Cancer · 2026

DOI: 10.1002/cncr.70478 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2026. Verfasst von Gayathri Ravi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Hematopoietic Stem Cell Transplantation, Multiple Myeloma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background Functional high‐risk (FHR) multiple myeloma (MM) was historically defined as progression within 18 months of starting therapy, with expected subsequent overall survival (OS)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsHematopoietic Stem Cell TransplantationMultiple MyelomaAdultAgedFemaleHumansMaleMiddle AgedDisease ProgressionTransplantation, AutologousMulticenter Studies as TopicClinical Trials, Phase II as Topic

Stichwörter der Autor:innen

CD38 antigenantibodiesantineoplasticsbispecificchimeric antigen receptor therapymonoclonal antibodymultiple myeloma

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.
  • Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
  • Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin, Madison, Wisconsin, USA.
  • Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
  • Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Pathology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.

ORCID-Profile: Binod Dhakal, Bhagirathbhai R Dholaria, Luciano J Costa

Zitieren

APA

Ravi, G., Dhakal, B., Callander, N. S., Medvedova, E., Dholaria, B. R., Godby, K. N., Bal, S., Huls, F., Silbermann, R. W., & Costa, L. J. (2026). Redefining functional high‐risk multiple myeloma in the context of upfront quadruplet therapy and autologous stem cell transplantation. Cancer. https://doi.org/10.1002/cncr.70478

Vancouver

Ravi G, Dhakal B, Callander NS, Medvedova E, Dholaria BR, Godby KN, et al. Redefining functional high‐risk multiple myeloma in the context of upfront quadruplet therapy and autologous stem cell transplantation. Cancer. 2026. doi:10.1002/cncr.70478

BibTeX
@article{Ravi2026,
  author = {Ravi, Gayathri and Dhakal, Binod and Callander, Natalie S and Medvedova, Eva and Dholaria, Bhagirathbhai R and Godby, Kelly N and Bal, Susan and Huls, Forest and Silbermann, Rebecca W and Costa, Luciano J},
  title = {Redefining functional high‐risk multiple myeloma in the context of upfront quadruplet therapy and autologous stem cell transplantation},
  journal = {Cancer},
  year = {2026},
  doi = {10.1002/cncr.70478}
}
Kostenlos starten →